Sanofi and AstraZeneca's preventive RSV therapy appears safe: FDA staff

Sanofi and AstraZeneca's preventive RSV therapy appears safe: FDA staff The companies are seeking the FDA's approval for use of the therapy in infants and children up to 24 months of age to protect them against lower respiratory tract disease that could cause pneumonia and bronchiolitis. https://ift.tt/JCfclTF

Comments

Popular posts from this blog

SC transfers PIL seeking implementation of law on mental health care to NHRC

Hospital-insurer conflict: Will latest circular by NMC help in reducing the pain of health insurance policyholders?

Over 9.19 crore hospital admissions facilitated under Ayushman Bharat since 2018